Tags

Type your tag names separated by a space and hit enter

IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases.
Clin Chim Acta 2012; 413(19-20):1683-8CC

Abstract

BACKGROUND/AIMS

IgA antibodies against tissue-transglutaminase (anti-tTG-IgA) and IgA and IgG antibodies against deamidated gliadin peptides (anti-DGP-IgA and anti-DGP-IgG) are considered specific for celiac disease (CD) whereas, patients with chronic liver disorders have an increased risk of latent CD development. We investigated the prevalence and clinical significance of anti-DGP-IgA, anti-DGP-IgG and anti-tTG-IgA in a large cohort of patients with chronic liver diseases.

METHODS

668 patients without gastrointestinal symptoms (426 viral hepatitis, 94 autoimmune liver diseases, 61 alcoholic disease, 46 non-alcoholic fatty liver disease, 41 with other liver disorders) were investigated by ELISAs (INOVA Diagnostics). Patients positive for at least one autoantibody invited for a small-intestinal biopsy and HLA-DQ typing.

RESULTS

Anti-DGP-IgA were detected in 8.5%, anti-DGP-IgG in only one (0.15%, P<0.001) and anti-tTG-IgA in 5.8% of patients (P=0.05). Fifty-two were anti-DGP-IgA(+)/anti-tTG-IgA(-), 34 anti-DGP-IgA(-)/anti-tTG-IgA(+), and 5 anti-DGP-IgA(+)/anti-tTG-IgA(+). Anti-DGP-IgA positivity was associated with older age (P<0.05), cirrhosis (P<0.05) and increased IgA (P<0.05) whereas, anti-tTG-IgA only with cirrhosis (P<0.05). Histology and HLA-typing compatible with CD was revealed in 4/14 anti-DGP-IgA(+)/anti-tTG-IgA(-), 0/13 anti-DGP-IgA(-)/anti-tTG-IgA(+) and 2/2 anti-DGP-IgA(+)/anti-tTG-IgA(+). All 6 patients diagnosed with CD were anti-DGP-IgA(+) and only 2 anti-tTG-IgA(+).

CONCLUSIONS

Although a significant number of patients had detectable CD-related autoantibodies, anti-DGP-IgA test seems better than anti-tTG-IgA for unmasking occult forms of CD in patients with chronic liver disorders. The known good performance for CD diagnosis of anti-DGP-IgG test was not confirmed in this specific group of patients.

Authors+Show Affiliations

Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22643316

Citation

Gatselis, Nikolaos K., et al. "IgA Antibodies Against Deamidated Gliadin Peptides in Patients With Chronic Liver Diseases." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 413, no. 19-20, 2012, pp. 1683-8.
Gatselis NK, Zachou K, Norman GL, et al. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin Chim Acta. 2012;413(19-20):1683-8.
Gatselis, N. K., Zachou, K., Norman, G. L., Tzellas, G., Speletas, M., Gabeta, S., ... Dalekos, G. N. (2012). IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clinica Chimica Acta; International Journal of Clinical Chemistry, 413(19-20), pp. 1683-8. doi:10.1016/j.cca.2012.05.015.
Gatselis NK, et al. IgA Antibodies Against Deamidated Gliadin Peptides in Patients With Chronic Liver Diseases. Clin Chim Acta. 2012 Oct 9;413(19-20):1683-8. PubMed PMID: 22643316.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. AU - Gatselis,Nikolaos K, AU - Zachou,Kalliopi, AU - Norman,Gary L, AU - Tzellas,George, AU - Speletas,Matthaios, AU - Gabeta,Stella, AU - Germenis,Anastasios, AU - Koukoulis,George K, AU - Dalekos,George N, Y1 - 2012/05/26/ PY - 2012/01/05/received PY - 2012/05/22/revised PY - 2012/05/22/accepted PY - 2012/5/31/entrez PY - 2012/5/31/pubmed PY - 2012/12/10/medline SP - 1683 EP - 8 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin. Chim. Acta VL - 413 IS - 19-20 N2 - BACKGROUND/AIMS: IgA antibodies against tissue-transglutaminase (anti-tTG-IgA) and IgA and IgG antibodies against deamidated gliadin peptides (anti-DGP-IgA and anti-DGP-IgG) are considered specific for celiac disease (CD) whereas, patients with chronic liver disorders have an increased risk of latent CD development. We investigated the prevalence and clinical significance of anti-DGP-IgA, anti-DGP-IgG and anti-tTG-IgA in a large cohort of patients with chronic liver diseases. METHODS: 668 patients without gastrointestinal symptoms (426 viral hepatitis, 94 autoimmune liver diseases, 61 alcoholic disease, 46 non-alcoholic fatty liver disease, 41 with other liver disorders) were investigated by ELISAs (INOVA Diagnostics). Patients positive for at least one autoantibody invited for a small-intestinal biopsy and HLA-DQ typing. RESULTS: Anti-DGP-IgA were detected in 8.5%, anti-DGP-IgG in only one (0.15%, P<0.001) and anti-tTG-IgA in 5.8% of patients (P=0.05). Fifty-two were anti-DGP-IgA(+)/anti-tTG-IgA(-), 34 anti-DGP-IgA(-)/anti-tTG-IgA(+), and 5 anti-DGP-IgA(+)/anti-tTG-IgA(+). Anti-DGP-IgA positivity was associated with older age (P<0.05), cirrhosis (P<0.05) and increased IgA (P<0.05) whereas, anti-tTG-IgA only with cirrhosis (P<0.05). Histology and HLA-typing compatible with CD was revealed in 4/14 anti-DGP-IgA(+)/anti-tTG-IgA(-), 0/13 anti-DGP-IgA(-)/anti-tTG-IgA(+) and 2/2 anti-DGP-IgA(+)/anti-tTG-IgA(+). All 6 patients diagnosed with CD were anti-DGP-IgA(+) and only 2 anti-tTG-IgA(+). CONCLUSIONS: Although a significant number of patients had detectable CD-related autoantibodies, anti-DGP-IgA test seems better than anti-tTG-IgA for unmasking occult forms of CD in patients with chronic liver disorders. The known good performance for CD diagnosis of anti-DGP-IgG test was not confirmed in this specific group of patients. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/22643316/IgA_antibodies_against_deamidated_gliadin_peptides_in_patients_with_chronic_liver_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(12)00292-6 DB - PRIME DP - Unbound Medicine ER -